Georgia's Online Cancer Information Center


back

Bladder Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Bladder Cancer
Cancer Type = Bladder Cancer
NCI ID Cancer Type Trial Name
There are currently 11 active Bladder Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary
NCT ID
NCT03288545
Protocol IDs
SGN22E-002
NCI-2017-01927
Treatment Sites (2)
Piedmont Cancer Institute
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab / BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer
NCT ID
NCT03519256
Protocol IDs
CA209-9UT
NCI-2018-01177
2017-003581-27
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
3.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
4.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Bladder Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
5.
A Phase II Study of Nivolumab Combined with Ipilimumab for Patients with Advanced Rare Genitourinary Tumors
Cancer Type
Adrenal Cancer, Bladder Cancer, Germ Cell Tumor, Penile Cancer, Prostate Cancer
NCT ID
NCT03333616
Protocol IDs
17-423
NCI-2018-00182
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Cancer Type
Bladder Cancer
NCT ID
NCT02108652
Protocol IDs
GO29293
7.
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT03091660
Protocol IDs
S1602
S1602
NCI-2016-00451
S1602
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
8.
An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.
Cancer Type
Bladder Cancer, Breast Cancer
NCT ID
NCT01953926
Protocol IDs
PUMA-NER-5201
NCI-2014-00495
2013-002872-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy
Cancer Type
Bladder Cancer
NCT ID
NCT01489813
Protocol IDs
EU2010-11
NCI-2014-02088
IRB00050273
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Atlanta
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
10.
Phase II Study of Adjuvant Conformal Radiotherapy in High Risk Bladder Cancer
Cancer Type
Bladder Cancer
NCT ID
NCT01954173
Protocol IDs
RAD2271-12
NCI-2013-01381
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
NCORP Trial
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Cancer Type
Bladder Cancer
NCT ID
NCT03244384
Protocol IDs
A031501
A031501
NCI-2017-01425
A031501
Treatment Sites (15)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Clinical Trials & Providers

Survivorship

About Us

Resources & Education

Media, News & Events

Patient Navigation

Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.